Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of July 5, 2026, ROIV trades at $35.13 with a market cap of $25.27B and a P/E ratio of -81.70. ROIV moved +0.34% today. Year to date, ROIV is +62.41%; over the trailing twelve months it is +220.24%. Its 52-week range spans $8.73 to $35.90. Analyst consensus is strong buy with an average price target of $36.72. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ROIV insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $35.13 |
| Market Cap | $25.27B |
| P/E Ratio | -81.70 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $35.90 |
| 52-Week Low | $8.73 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.26M |
| Net Income | $-397.91M |
| Gross Margin | 0.00% |
8 analysts cover ROIV: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.72.